Mutation Testing in Charcot-Marie-Tooth Neuropathy.

Area of Science:

• Genetics and Neurology
• Molecular Diagnostics
• Peripheral Neuropathies

Background:

• Charcot-Marie-Tooth (CMT) neuropathy is a group of inherited disorders affecting peripheral nerves.
• Accurate genetic diagnosis is crucial for understanding disease mechanisms and patient management.
• Previous approaches involved broad genetic testing for CMT-associated genes.

Purpose of the Study:

• To determine the most effective strategy for mutation testing in Charcot-Marie-Tooth (CMT) neuropathy.
• To evaluate the diagnostic yield of testing for CMT1A duplication and point mutations in connexin32, PMP22, and P0.
• To optimize genetic testing protocols for different CMT subtypes.

Main Methods:

• Patients with CMT phenotype and median motor conduction velocities < 50 m/sec were analyzed.
• Genetic testing included CMT1A duplication and point mutations in connexin32, peripheral myelin protein 22 (PMP22), and myelin protein zero (P0).
• Specific patient selection criteria were applied based on family history and neurophysiological indicators (e.g., CMTX, Dejerine-Sottas syndrome).

Main Results:

• Connexin32 mutations were primarily identified in families without male-to-male CMT inheritance and with CMTX indicators.
• PMP22 and P0 mutations were found in Dejerine-Sottas cases or severe dominant CMT1 phenotypes.
• Broad, 'blind' genetic testing for these mutations in CMT1 families yielded limited diagnostic value.

Conclusions:

• Targeted genetic testing strategies significantly improve the detection rate of specific CMT mutations.
• Patient selection based on clinical and neurophysiological characteristics is essential for efficient mutation analysis.
• Broad genetic screening for connexin32, P0, and PMP22 mutations in all CMT1 families is not recommended.